Shanghai OPM Biosciences (688293.SH) plans to increase its stake in CRO company Pengli Biological by 100% to enhance its overseas influence. It will resume trading on February 10th.

Shanghai OPM Biosciences (688293.SH) released a plan to issue shares and pay cash to acquire assets, as well as raise matching funds. The listed company plans to issue shares and pay cash to PL HK, Jiaxing Huituo, Redstone Venture, Shanghai Genius, Gusheng Investment, TF PL, Gao Ling Chenjun, Hangzhou Taige, Nantong Dongzheng, Jiangxi Jilin, Zhongjin Qichen, Jiaxing Hetuo, Suzhou Chenling, Mifang Kangjian Investment, Pingyang Guokai, Mifang Pharmaceutical Investment, Wuhan Taiming, Shanghai Jingdu, Wang Guo'an, Shanghai Beijimin, Shanghai Yansheng, Gao Ling Qirui, Zhuhai Liangheng, Jiaxing Yuanlai, Shanghai Junpeng, Xiamen Yinglian, Shanghai Chengxi, Qingdao Qiandao, Shanghai Lichen, Suzhou Guofa, Qianting Zhi, a total of 31 trading partners to purchase 100.00% equity of Pengli Bioscience, and raise matching funds. The issue price is 32.00 yuan/share. Pengli Bioscience focuses on pre-clinical CRO technology services for innovative drugs, especially in the pre-clinical pharmacology and pharmacokinetics research, it has a strong competitive advantage and is an important participant in the early stage of innovative drug development. Through this transaction, the listed company and the target company will combine innovative drug research and development with process production, forming significant synergies in business and customer coordination, overseas strategic layout coordination, operational management system coordination, etc., achieving complementary advantages. After this transaction, the listed company's development pattern of "product + service" dual-wheel drive will be further improved, deepening the ability to provide one-stop products and services for the biopharmaceutical industry, enhancing profitability and strengthening customer stickiness. At the same time, the listed company can integrate the target company's mature international business expansion team, and with its established good cooperation relationship with multinational pharmaceutical companies, accelerate the promotion of its own cell products and services in overseas markets, effectively enhance the brand influence and market share of the listed company in overseas markets. Finally, by drawing on the excellent operation and management system of the target company and further optimizing resource allocation, the competitive strength of the listed company's service sector will be greatly enhanced, and its market position will be further highlighted. According to relevant regulations, after applying to the Shanghai Stock Exchange, the company's stock is expected to resume trading from Monday, February 10, 2025.